ONCOLOGY PHARMA INC (ONPH:OTCMKTS)
$0.0502 -0.0198 (-28.2857%)
Analysed ONCOLOGY PHARMA INC (ONPH:OTCMKTS) News Sources
ISPOR's Oncology and Statistical Methods Special Interest Groups Selects DistillerSR for Joint Systematic Review Project
21-08-2025
yahoo.com
Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study
26-10-2025
yahoo.com
Guardant Health Catapults 234%; Sets Up With Strong Sales Outlook
08-01-2026
yahoo.com
The clinical candidates pharma execs are tracking
16-01-2026
pharmavoice.com
AstraZeneca’s growth engine stays on track despite cost pressures
10-02-2026
proactiveinvestors.com
Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary
20-03-2026
moby.co
Johnson & Johnson Q1 2026 Earnings Call Summary
14-04-2026
moby.co
GSK reaffirms 2026 guidance after strong first-quarter performance
29-04-2026
proactiveinvestors.com
McKesson Q4 Earnings Call Highlights
11-05-2026
marketbeat.com
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
15-07-2026
yahoo.com
What is the current price of ONCOLOGY PHARMA INC (ONPH:OTCMKTS)?
The current price of ONCOLOGY PHARMA INC (ONPH:OTCMKTS) is $0.0502.
ONCOLOGY PHARMA INC (ONPH:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ONCOLOGY PHARMA INC (ONPH:OTCMKTS) since the previous trading day is $-0.0198.
ONCOLOGY PHARMA INC (ONPH:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ONCOLOGY PHARMA INC (ONPH:OTCMKTS) since the previous trading day is -28.2857%.
What is the most recent average sentiment score for ONCOLOGY PHARMA INC (ONPH:OTCMKTS)?
The most recent average sentiment score for ONCOLOGY PHARMA INC (ONPH:OTCMKTS) is 66 out of 100.
What is the most recent average sentiment for ONCOLOGY PHARMA INC (ONPH:OTCMKTS)?
The most recent sentiment for ONCOLOGY PHARMA INC (ONPH:OTCMKTS) is .
SEC-8K** Filing Available For ONCOLOGY PHARMA INC (ONPH:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.